Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

McKinsey
Baxter
Boehringer Ingelheim
Merck
AstraZeneca
Dow

Last Updated: November 22, 2019

DrugPatentWatch Database Preview

ADASUVE Drug Profile

See Plans and Pricing

« Back to Dashboard

Drug patent expirations by year for ADASUVE
Drug Prices for ADASUVE

See drug prices for ADASUVE

Generic Entry Opportunity Date for ADASUVE
Generic Entry Date for ADASUVE*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
POWDER;INHALATION

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for ADASUVE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Advocate Health CareN/A
Teva Branded Pharmaceutical Products, R&D Inc.Phase 1
Alexza Pharmaceuticals, Inc.Phase 1

See all ADASUVE clinical trials

Synonyms for ADASUVE
13-chloro-10-(4-methylpiperazin-1-yl)-2-oxa-9-azatricyclo[9.4.0.0^{3,8}]pentadeca-1(11),3,5,7,9,12,14-heptaene
13-chloro-10-(4-methylpiperazin-1-yl)-2-oxa-9-azatricyclo[9.4.0.0;{3,8}]pentadeca-1(11),3(8),4,6,9,12,14-heptaene
1977-10-2
2-Chloro-11-(4-methyl-1-piperazinyl)-dibenz(b,f)(1,4)oxazepine
2-Chloro-11-(4-methyl-1-piperazinyl)dibenz(b,f)(1,4)oxazepine
2-Chloro-11-(4-methyl-1-piperazinyl)dibenz[b,f][1,4]oxazepine
2-chloro-11-(4-methylpiperazin-1-yl)dibenzo[b,f][1,4]oxazepine
2-Chloro-11-(4-methylpiperazino)dibenz[b,f][1,4]oxazepine
2-Chloro-11-(4-methylpiperazino)dibenzo(b,f)(1,4)oxazepine
27833-64-3 (succinate)
3785AH
54810-23-0 (mono-hydrochloride)
8-chloro-6-(4-methylpiperazin-1-yl)benzo[b][1,4]benzoxazepine
8-chloro-6-(4-methylpiperazin-1-yl)benzo[b][1,5]benzoxazepine
8-chloro-6-(4-methylpiperazino)benzo[b][1,4]benzoxazepine;succinic acid
977L102
AB00053735_15
AB00053735_16
AC1L1H3Z
AC1Q3ZWR
Adasuve (TN)
AKOS030526111
API0006785
AZ-004
BDBM22871
BPBio1_000226
BRD-K39915878-036-04-6
BRD-K39915878-036-05-3
BRD-K39915878-036-15-2
BRN 0626753
BSPBio_000204
BSPBio_003479
C07104
C18H18ClN3O
CCG-204805
CHEBI:50841
CHEMBL831
CL 62,362
CL 62362
CL-62362
CL-71,563
CL-71563
CL71,563
Cloxazepine
CS-1105
D02340
DB00408
Dibenz(b,f)(1,4)oxazepine, 2-chloro-11-(4-methyl-1-piperazinyl)-
Dibenz[b,f][1,4]oxazepine, 2-chloro-11-(4-methyl-1-piperazinyl)-
Dibenzacepin
Dibenzoazepine
DivK1c_006919
DTXSID7023229
EINECS 217-835-3
GTPL205
HF 3170
HF3170
HSDB 3111
HY-17390
Hydrofluoride 3170
KBio1_001863
KBio2_000835
KBio2_003403
KBio2_005971
KBio3_002983
KBioSS_000835
L001085
LER583670J
Lopac0_000720
Lossapina
Lossapina [DCIT]
Loxapac
Loxapin
Loxapina
Loxapina [INN-Spanish]
loxapine
Loxapine (DMSO)
Loxapine (USAN/INN)
Loxapine (water)
Loxapine [USAN:BAN:INN]
Loxapine [USAN:INN:BAN]
Loxapinsuccinate
Loxapinum
Loxapinum [INN-Latin]
Loxepine
Loxitane
LOXITANE C
Loxitane IM
Loxitane Intramuscular
Loxitane-C Oral Suspension
LS-61562
LW 3170
NCGC00021145-01
NCGC00021145-02
NCGC00021145-03
NCGC00021145-04
NCGC00021145-05
NCGC00021145-06
NCGC00021145-07
NCGC00021145-08
NCGC00022279-03
NCGC00022279-04
NCGC00022279-05
Oxilapine
PDSP1_001058
PDSP2_001042
Prestwick0_000132
Prestwick1_000132
Prestwick2_000132
Prestwick3_000132
QTL1_000050
S 805
S-805
SCHEMBL94146
SPBio_001814
SPBio_002143
SpecPlus_000823
Spectrum_000355
Spectrum2_001737
Spectrum3_001830
Spectrum5_001857
Staccato loxapine
SUM 3170
SUM-3170
UNII-LER583670J
W-5098
XJGVXQDUIWGIRW-UHFFFAOYSA-N
ZINC19796158

US Patents and Regulatory Information for ADASUVE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Alexza Pharms ADASUVE loxapine POWDER;INHALATION 022549-001 Dec 21, 2012 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Alexza Pharms ADASUVE loxapine POWDER;INHALATION 022549-001 Dec 21, 2012 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Alexza Pharms ADASUVE loxapine POWDER;INHALATION 022549-001 Dec 21, 2012 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Alexza Pharms ADASUVE loxapine POWDER;INHALATION 022549-001 Dec 21, 2012 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for ADASUVE

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1389098 C01389098/01 Switzerland   Start Trial PRODUCT NAME: LOXAPINUM; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 65461 13.12.2016
1389098 473 Finland   Start Trial
1389098 SPC/GB13/055 United Kingdom   Start Trial PRODUCT NAME: LOXAPINE; REGISTERED: UK EU/1/13/823/001 20130220; UK EU/1/13/823/002 20130220
1389098 CA 2013 00046 Denmark   Start Trial PRODUCT NAME: LOXAPIN; REG. NO/DATE: EU/1/13/823/001-002 20130220
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Medtronic
Harvard Business School
Baxter
Boehringer Ingelheim
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.